Krishnaswamy Gajaraj, MD
Psychiatry · Randolph, MANPI 1962488395
Payments from drug & device makers
Across 101 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$820
- Vanda Pharmaceuticals Inc.$435
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$367
- E.r. Squibb & Sons, L.L.C.$303
- Otsuka America Pharmaceutical, Inc.$188
- Johnson & Johnson$170
- plus $506 from 9 others
What the payments were for
- Food & beverage$2,45688%
- Education$33412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $820 |
| Vanda Pharmaceuticals Inc. | 26 | $435 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $367 |
| E.r. Squibb & Sons, L.L.C. | 4 | $303 |
| Otsuka America Pharmaceutical, Inc. | 5 | $188 |
| Johnson & Johnson | 3 | $170 |
| Sunovion Pharmaceuticals Inc. | 4 | $168 |
| Lundbeck LLC | 7 | $152 |
| Alkermes, Inc. | 3 | $48 |
| Ironshore Pharmaceuticals Inc. | 1 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Corium, LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$246
- VRAYLAR$231
- INVEGA SUSTENNA$136
- CAPLYTA$108
- ABILIFY MAINTENA$104
- ABILIFY ASIMTUFII$104
How this compares
$2,791 in reported general payments places this provider in the 85th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $4,803 |
| TrintellixVortioxetine Hydrobromide | 11 | $4,764 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 70 | $4,702 |
| Aripiprazole | 48 | $3,228 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 97 | $2,777 |
| Oxcarbazepine | 35 | $1,705 |
| Duloxetine Hcl | 23 | $1,517 |
| Clonazepam | 265 | $1,484 |
| Buspirone Hcl | 53 | $1,401 |
| Trazodone Hcl | 95 | $1,215 |
| Fluphenazine Hcl | 13 | $1,163 |
| Alprazolam | 73 | $1,135 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 42 | $1,095 |
| Lorazepam | 137 | $1,063 |
| Quetiapine Fumarate | 97 | $704 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Randolph
- Lee CohenBoston$7M
- Dyanna DomiliciBoston$5.8M
- Arkadiy StolyarBelmont$3.3M
- Maurizio FavaBoston$2.8M
- Marc ShayAmesbury$1.7M
- Martha StarkNewton$1.6M
- Hadine JoffeBoston$1.5M
- Malini NairWinchester$1M
- Xiaoduo FanWorcester$950K
- Anthony RothschildWorcester$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.